Increased non-perfusion areas, foveal avascular zones and retinal ischemia as well as reduced retinal vascular density have been reported in some clinical studies of anti-VEGF therapy for DME and wet age-related macular degeneration (AMD) [29,30,31,32]. This evidence concerns the gene VEGFA and age-related macular degeneration.